The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

• Status: Recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the research is to see if Upneeq ( oxymetazoline 0.1% ophthalmic solution) has an effect on eyelid position, eye redness, or patient-perceived appearance of the eyes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Miami
• Treatments: Ophthalmic Solutions; Oxymetazoline; Pharmaceutical Solutions; Phenylephrine

Criteria

Inclusion Criteria:

• Adults age 18 and above able to provide informed consent to participate

• Subject with stable ocular health, defined as no ocular conditions requiring ongoing topical therapy or recent surgical intervention

Exclusion Criteria:

• Adults unable to consent

• Individuals less than 18 years of age

• Prisoners

• Pregnant women.

• Known contradictions or sensitivities to study medication (oxymetazoline)

• Ocular surgery within the past 3 months or refractive surgery within the past six months

• Grossly abnormal lid margins, anatomical abnormalities, previous eyelid or orbital surgery

• Variable ptosis or eyelid position (e.g., myasthenia gravis, thyroid eye disease, or blepharospasm)

• Any ocular or systemic condition that, in the opinion of the investigator, would confound study data, interfere with the subject's study participation, or affected the subject's safety or trial parameters

• Presence of an active ocular infection

• Prior (within 5 days of beginning study treatment) use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines (including over the counter and herbal topical ophthalmic medications), phenylephrine dilating drops, any other topical ophthalmic agents

• Inability to sit comfortably for 15 - 30 minutes